Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Videos

Modified FOLFOXIRI Plus Cetuximab as the First-Line Treatment for Patients With RAS Wild-Type Metastatic Colorectal Cancer

Updated Survival Data From the Phase 2 DEEPER Trial

Featuring Yu Sunakawa, MD


At the 2023 ESMO World Congress on Gastrointestinal Cancers, Yu Sunakawa, MD, St. Marianna University School of Medicine, Kawasaki, Japan, presented updated survival data from the phase 2 DEEPER trial, evaluating modified(m)-FOLFOXIRI plus cetuximab vs m-FOLFOXIRI plus bevacizumab among patients with RAS wild-type metastatic colorectal cancer. Previously, it was reported that mFOLFOXIRI plus cetuximab showed significant better depth of response.

From this updated data, Dr Sunakawa concluded,  “The modified-FOLFOXIRI plus cetuximab regimen could be a good option for upfront chemotherapy in metastatic colorectal cancer patients with RAS/BRAF wild-type and left-sided primary tumors.”

Transcript:

 


Source:

Sunakawa Y, Shiozawa M, Watanabe, T, et al. Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment for RAS and BRAF wild-type metastatic colorectal cancer: Updated survival analysis of the DEEPER trial by JACCRO. Presented at the 2023 ESMO World Congress on Gastrointestinal Cancers; June 28-July 1, 2023; Barcelona, Spain. Abstract SO-25

© 2023 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.

Advertisement

Advertisement

Advertisement

Advertisement